MS4A1 and diffuse large B-cell lymphoma: These genes may serve as potential therapeutic targets and prognostic indicators for improving rituximab sensitivity and reversing drug tolerance in cancer cells, given their significant role in regulating MS4A1 expression in hypoxic DLBCL tumors.